ICCA-LRI and JRC Workshop – 17 and 18 June 2014 Lugano

31 March 2014

mhealth for improving quality of life. Enhancing cancer supportive care

26 February 2014

Helsinn Group’s representative office in China: Official inauguration

4 December 2013

Helsinn and Chugai Pharma Marketing enter into agreement for rights of Anamorelin, currently in development for treatment of anorexia-cachexia syndrome related to non-small cell lung cancer in top EU markets

12 November 2013

10 young students from the Sopraceneri area receive Helsinn Advanced Synthesis SA 2013/2014 educational scholarships

9 October 2013

Helsinn to launch sales organization in the United States

4 October 2013

Very positive Clinical Phase I/IIa results for Calcipotriol AKVANO formulation for the treatment of Psoriasis

13 September 2013

Helsinn Group and Eisai Inc. Announce Top-Line Results for Pivotal Studies of the Investigational Fixed-Dose Combination of Netupitant and Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting

16 May 2013

NEWSOur new plant for CHO based mAb or Recombinant Protein manufacturing is ready for the qualification phase

19 February 2013

Helsinn Grants Specialised Therapeutics Australia (STA) Rights to Anamorelin

22 October 2012